The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.
NAD⁺ precursors and EGCG may increase hair density, but users report mixed results with no significant hair gains. Some users suggest combining these with finasteride or dutasteride for better results.
The user is experiencing thicker hair after using oral minoxidil, dutasteride, biotin, collagen shampoo with rosemary, and ketoconazole. They are considering adding a derma roller to their regimen for potential benefits.
The user has been using 5% minoxidil once daily and microneedling with a 1.5 mm dermaroller weekly for three months, considering increasing minoxidil usage but avoiding finasteride due to libido concerns. Another person suggests considering other treatments like RU58841, alfatradiol, topical finasteride, clascoterone, or saw palmetto since not using a DHT blocker could be less effective.
Finasteride, minoxidil, dermarolling, and topical antiandrogens are effective for hair regrowth. Future treatments may include CB0301 and hair cloning.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
The post discusses a DIY Dutasteride Mesotherapy procedure for hair regrowth, supplemented with oral Minoxidil. The user describes the process, including preparation, equipment used, and initial results, expressing excitement for future outcomes.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.